FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377042583> ?p ?o ?g. }

• W4377042583 endingPage "989" @default.
• W4377042583 startingPage "989" @default.
• W4377042583 abstract "(1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term protection conferred by vaccination is not known. (2) Objectives: 1. To determine the adverse effects associated with BNT162B2 vaccination in children and young adults with cancer. 2. To assess its efficacy in stimulating immunological response and in preventing severe COVID-19 disease. (3) Methods: Retrospective single-center study evaluating patients aged 8 to 22 years, with cancer, who underwent vaccination from January 2021 to June 2022. ELISA serologies and serum neutralization were collected monthly from the first injection. Serologies below 26 were considered negative, while those above 264 BAU/mL were considered positive and indicative of protection. Antibodies titers were considered positive above 20. Data on adverse events and infections were collected. (4) Results: 38 patients were included (M/F = 1.7, median age 16 years), of whom 63% had a localized tumor and 76% were undergoing treatment at the time of the first vaccination. Two or three vaccine injections were administered in 90% of patients. Adverse events were mainly systemic and not severe, except for seven grade 3 toxicities. Four cancer-related deaths were reported. Median serology was negative the month following the first vaccination and became protective during the third month. At 3 and 12 months, median serology was 1778 and 6437 BAU/mL, respectively. Serum neutralization was positive in 97% of the patients. COVID-19 infection occurred despite vaccination in 18%; all were mild forms. (5) Conclusions: In children and young adults with cancer, vaccination was well tolerated and conferred effective serum neutralization. COVID-19 infections were mild, and vaccine seroconversion persisted after 12 months in most patients. The value of additional vaccination should be further established." @default.
• W4377042583 created "2023-05-19" @default.
• W4377042583 creator A5028343092 @default.
• W4377042583 creator A5040352199 @default.
• W4377042583 creator A5041372516 @default.
• W4377042583 creator A5045701704 @default.
• W4377042583 creator A5051095516 @default.
• W4377042583 creator A5052649527 @default.
• W4377042583 creator A5060300844 @default.
• W4377042583 creator A5067395185 @default.
• W4377042583 date "2023-05-16" @default.
• W4377042583 modified "2023-10-18" @default.
• W4377042583 title "BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up" @default.
• W4377042583 cites W3008028633 @default.
• W4377042583 cites W3018829510 @default.
• W4377042583 cites W3023722385 @default.
• W4377042583 cites W3043138331 @default.
• W4377042583 cites W3046168147 @default.
• W4377042583 cites W3058931099 @default.
• W4377042583 cites W3111255098 @default.
• W4377042583 cites W3167712899 @default.
• W4377042583 cites W3170782268 @default.
• W4377042583 cites W3174017401 @default.
• W4377042583 cites W3174476213 @default.
• W4377042583 cites W3182716729 @default.
• W4377042583 cites W3191433703 @default.
• W4377042583 cites W3196277563 @default.
• W4377042583 cites W3197987398 @default.
• W4377042583 cites W3198468926 @default.
• W4377042583 cites W3201182224 @default.
• W4377042583 cites W3208395787 @default.
• W4377042583 cites W3212487860 @default.
• W4377042583 cites W3213528330 @default.
• W4377042583 cites W4200320281 @default.
• W4377042583 cites W4212835565 @default.
• W4377042583 cites W4220839898 @default.
• W4377042583 cites W4220980350 @default.
• W4377042583 cites W4221060091 @default.
• W4377042583 cites W4224260129 @default.
• W4377042583 cites W4225130422 @default.
• W4377042583 cites W4280534132 @default.
• W4377042583 cites W4283455902 @default.
• W4377042583 cites W4288051435 @default.
• W4377042583 cites W4288444710 @default.
• W4377042583 cites W4289985807 @default.
• W4377042583 cites W4296891086 @default.
• W4377042583 cites W4307459808 @default.
• W4377042583 cites W4310521947 @default.
• W4377042583 cites W4311691594 @default.
• W4377042583 doi "https://doi.org/10.3390/vaccines11050989" @default.
• W4377042583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37243093" @default.
• W4377042583 hasPublicationYear "2023" @default.
• W4377042583 type Work @default.
• W4377042583 citedByCount "0" @default.
• W4377042583 crossrefType "journal-article" @default.
• W4377042583 hasAuthorship W4377042583A5028343092 @default.
• W4377042583 hasAuthorship W4377042583A5040352199 @default.
• W4377042583 hasAuthorship W4377042583A5041372516 @default.
• W4377042583 hasAuthorship W4377042583A5045701704 @default.
• W4377042583 hasAuthorship W4377042583A5051095516 @default.
• W4377042583 hasAuthorship W4377042583A5052649527 @default.
• W4377042583 hasAuthorship W4377042583A5060300844 @default.
• W4377042583 hasAuthorship W4377042583A5067395185 @default.
• W4377042583 hasBestOaLocation W43770425831 @default.
• W4377042583 hasConcept C121608353 @default.
• W4377042583 hasConcept C126322002 @default.
• W4377042583 hasConcept C159654299 @default.
• W4377042583 hasConcept C167135981 @default.
• W4377042583 hasConcept C187212893 @default.
• W4377042583 hasConcept C197934379 @default.
• W4377042583 hasConcept C203014093 @default.
• W4377042583 hasConcept C205545832 @default.
• W4377042583 hasConcept C22070199 @default.
• W4377042583 hasConcept C2779134260 @default.
• W4377042583 hasConcept C3008058167 @default.
• W4377042583 hasConcept C32611913 @default.
• W4377042583 hasConcept C45189115 @default.
• W4377042583 hasConcept C524204448 @default.
• W4377042583 hasConcept C71924100 @default.
• W4377042583 hasConceptScore W4377042583C121608353 @default.
• W4377042583 hasConceptScore W4377042583C126322002 @default.
• W4377042583 hasConceptScore W4377042583C159654299 @default.
• W4377042583 hasConceptScore W4377042583C167135981 @default.
• W4377042583 hasConceptScore W4377042583C187212893 @default.
• W4377042583 hasConceptScore W4377042583C197934379 @default.
• W4377042583 hasConceptScore W4377042583C203014093 @default.
• W4377042583 hasConceptScore W4377042583C205545832 @default.
• W4377042583 hasConceptScore W4377042583C22070199 @default.
• W4377042583 hasConceptScore W4377042583C2779134260 @default.
• W4377042583 hasConceptScore W4377042583C3008058167 @default.
• W4377042583 hasConceptScore W4377042583C32611913 @default.
• W4377042583 hasConceptScore W4377042583C45189115 @default.
• W4377042583 hasConceptScore W4377042583C524204448 @default.
• W4377042583 hasConceptScore W4377042583C71924100 @default.
• W4377042583 hasIssue "5" @default.
• W4377042583 hasLocation W43770425831 @default.
• W4377042583 hasLocation W43770425832 @default.
• W4377042583 hasLocation W43770425833 @default.

• next